Gossamer Bio, Inc. (GOSS)
- Previous Close
1.0500 - Open
1.0600 - Bid 1.0000 x 400
- Ask 1.0600 x 100
- Day's Range
1.0300 - 1.1191 - 52 Week Range
0.4990 - 1.5500 - Volume
2,039,955 - Avg. Volume
1,616,529 - Market Cap (intraday)
238.582M - Beta (5Y Monthly) 1.82
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2500 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.61
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
www.gossamerbio.comRecent News: GOSS
View MorePerformance Overview: GOSS
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GOSS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GOSS
View MoreValuation Measures
Market Cap
238.58M
Enterprise Value
146.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.07
Price/Book (mrq)
8.09
Enterprise Value/Revenue
1.28
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-49.28%
Return on Assets (ttm)
-11.94%
Return on Equity (ttm)
-122.54%
Revenue (ttm)
114.7M
Net Income Avi to Common (ttm)
-56.53M
Diluted EPS (ttm)
-0.2500
Balance Sheet and Cash Flow
Total Cash (mrq)
294.52M
Total Debt/Equity (mrq)
687.92%
Levered Free Cash Flow (ttm)
-16.7M